Castle Biosciences (CSTL) news
Recent news
Castle Biosciences to begin Nasdaq Texas listing today under CSTL
AInvest Wire · Aug 17, 2026Castle Biosciences approved for dual listing on Nasdaq Texas
Castle Biosciences, Inc. (Nasdaq: CSTL) has been approved for a dual listing of its common stock on Nasdaq Texas, LLC, effective August 17, 2026. The company's common stock, which is already listed on The Nasdaq Global Market, will now also trade on Nasdaq Texas under the same ticker symbol "CSTL".…
AInvest Wire · Aug 17, 2026Castle Biosciences Q2 pretax profit USD -1.69 million
Castle Biosciences (Nasdaq: CSTL) reported a pretax loss of USD -1.69 million for the second quarter of 2025, reflecting ongoing financial challenges in its operations during the period. The company, which specializes in precision diagnostics for dermatologic and gastroenterological diseases,…
AInvest Wire · Jul 30, 2026Castle Biosciences' chief financial officer Frank Stokes named a 2026 CFO Awards honoree by the Houston Business Journal
AInvest Wire · Jun 23, 2026Castle Biosciences shares rise 11% on discovering data for potential complementary tests
AInvest Wire · Nov 3, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.